Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Pembrolizumab monotherapy has been approved for the first- and second-line treatment of patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC). Testing for PD-L1 expression with the PD-L1 immunohistochemistry (IHC) 22C3 companion diagnostic assay, which gives a tumor proportion s...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Vis Exp
Hoofdauteurs: Ilié, Marius, Ngo-Mai, Mélanie, Long-Mira, Elodie, Lassalle, Sandra, Butori, Catherine, Bence, Coraline, Hamila, Marame, Hofman, Véronique, Hofman, Paul
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MyJove Corporation 2018
Onderwerpen:
Cancer Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6235290/
https://ncbi.nlm.nih.gov/pubmed/30320751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3791/58082
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items